Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, People's Republic of China.
Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.
BMC Gastroenterol. 2021 Nov 19;21(1):433. doi: 10.1186/s12876-021-02015-w.
The intestinal microbiota is thought to be involved in the occurrence of inflammatory bowel disease in remission with irritable bowel syndrome (IBS)-type symptoms, but the specific distinct profile of these bacteria remains unclear. This cross-sectional study aims to investigate the fecal microbiota profiling in patients with these diseases.
Fecal samples from 97 subjects, including Crohn's disease patients in remission with IBS-type symptoms (CDR-IBS) or without IBS-type symptoms (CDR-IBS), ulcerative colitis patients in remission with IBS-type symptoms (UCR-IBS) or without IBS-type symptoms (UCR-IBS), IBS patients and healthy controls, were collected and applied 16S ribosomal DNA (rDNA) gene sequencing. The V4 hypervariable regions of 16S rDNA gene were amplified and sequenced by the Illumina MiSeq platform. The differences in the sample diversity index in groups were analyzed with R software.
The richness of the intestinal microbiota in the CDR-IBS group was markedly lower than those in the control and IBS groups based on the analysis of observed species and the Chao index (P < 0.05). The observed species index in the CDR-IBS group was higher than that in the CDR-IBS group (median index: 254.8 vs 203, P = 0.036). No difference was found in alpha diversity between UCR patients with IBS-type symptoms and those without related symptoms. At the genus level, the number of Faecalibacterium in CDR patients with IBS-type symptoms increased significantly, while Fusobacterium decreased versus those without such symptoms (mean relative abundance of Faecalibacterium: 20.35% vs 5.18%, P < 0.05; Fusobacterium: 1.51% vs 5.2%, P < 0.05). However, compared with the UCR-IBS group, the number of Faecalibacterium in the UCR-IBS group decreased, while the number of Streptococcus increased, but there was no significant difference in the genus structure. The abundance and composition of the microbiota of IBS patients were not distinct from those of healthy controls.
The IBS-type symptoms in CD patients in remission may be related to an increase in Faecalibacterium and a decrease in Fusobacterium. The IBS-type symptoms in UC patients in remission cannot be explained by changes in the abundance and structure of the intestinal microbiota.
肠道微生物群被认为与缓解期炎症性肠病伴有肠易激综合征（IBS）样症状有关，但这些细菌的具体特征仍不清楚。本横断面研究旨在探讨这些疾病患者的粪便微生物群特征。
收集 97 例患者的粪便样本，包括缓解期伴有 IBS 样症状的克罗恩病患者（CDR-IBS）或无 IBS 样症状的患者（CDR-IBS）、缓解期伴有 IBS 样症状的溃疡性结肠炎患者（UCR-IBS）或无 IBS 样症状的患者（UCR-IBS）、IBS 患者和健康对照者。应用 16S 核糖体 DNA（rDNA）基因测序。采用 Illumina MiSeq 平台扩增和测序 16S rDNA 基因 V4 高变区。采用 R 软件分析组间样本多样性指数的差异。
基于观察物种和 Chao 指数分析，CDR-IBS 组肠道微生物群的丰富度明显低于对照组和 IBS 组（P<0.05）。CDR-IBS 组的观察物种指数高于 CDR-IBS 组（中位数指数：254.8 比 203，P=0.036）。伴有 IBS 样症状的 UCR 患者与不伴有相关症状的患者之间的 alpha 多样性无差异。在属水平上，CDR 伴有 IBS 样症状患者的 Faecalibacterium 数量显著增加，而 Fusobacterium 数量减少（Faecalibacterium 的平均相对丰度：20.35%比 5.18%，P<0.05；Fusobacterium：1.51%比 5.2%，P<0.05）。然而，与 UCR-IBS 组相比，UCR-IBS 组的 Faecalibacterium 数量减少，而链球菌数量增加，但属结构无显著差异。IBS 患者的微生物群丰富度和组成与健康对照者无明显差异。
缓解期 CD 患者的 IBS 样症状可能与 Faecalibacterium 增加和 Fusobacterium 减少有关。缓解期 UC 患者的 IBS 样症状不能用肠道微生物群丰度和结构的变化来解释。
